
|Videos|June 30, 2022
What the impact of 44-week aflibercept data may mean in a real-world setting
Author(s)Sheryl Stevenson, Emily Kaiser Maharjan
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
5


















































.png)


